Exogenously administered IL‐6 enhances development of fatty lesions in mice (Huber et al., 1999), while in man this cytokine is enhances endothelial dysfunction and aortic stiffness: rheumatoid arthritis patients treated with anti‐IL‐6 therapy displayed reduced articular inflammation and decreased endothelial dysfunction (Protogerou et al., 2011). The gene discussed is IL6; the disease is rheumatoid arthritis.